#inter-partes-review-ipr

#inter-partes-review-ipr

Bayer's U.S. Patent No. 10,828,310, which claims methods for reducing cardiovascular events in certain patients by administering specific doses of rivaroxaban (2.5 mg twice daily) and aspirin (75-100 mg daily) "in amounts that are clinically proven effective." Generic manufacturers Mylan, Teva, and Invagen successfully challenged the patent in IPR proceedings - finding the claim term non-limiting. The Federal Circuit agreed that the term did not provide patentable weight - but through a different analytical path.

The fact that patents subjected to an inter partes review (IPR) are "specially selected" is the very reason that this class of patents are a suitable vehicle for studying the cited evidence. The actual evidence cited is what determines "the underlying actual quality of issued patents." Understanding how patent information evidence is missed during examination will identify the root cause of examination errors, both allowance errors and rejection errors.